With a revenue increase of 8.17% in the third quarter 2026, year on year to cumulative value of $730 million, Ultragenyx Pharmaceutical Inc 's revenue per employee grew on a trailing twelve months basis to $ 532,662. The productivity of Ultragenyx Pharmaceutical Inc 's employees was 0.0%, above the company average. Within the Healthcare sector Employees of 180 other companies have achieved higher revenue per employee. While Ultragenyx Pharmaceutical Inc 's total ranking has deteriorated compared to the previous quarter from 1230 to 1658. Ultragenyx Pharmaceutical Inc has 1,371 employees.
Ultragenyx Pharmaceutical Inc. Strengthens Workforce and Growth Potential Through Strategic Stock Grant InitiativesOn March 19, 2025, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company specializing in therapies for rare and ultrarare diseases, announced the granting of 21,806 restricted stock units (RSUs) to 16 newly hired non-executive officers. This initiative, approved by the company s compensation committee, falls under the Ultragenyx Employment Inducement Plan and aligns with Nasdaq Listing Rule 5635(c)(4). The RSUs were granted with a grant date of March 16, 2025, as part of a proactive strategy to attract and retain top talent essential for the company’s ongoing innovation and success.This news comes against a backdrop of impressive financial performance, with Ultragenyx reporting a revenue per employee growth to $439,052 over the trailing twelve months. The company’s revenue increased by 29.42% in the fourth quarter of 2024, reaching a cumulative value of $560 million—a record for the company. However, while Ultragenyx continues to perform strongly, its overall ranking among peers in the healthcare sector has slipped to 45th compared to the previous quarter, indicating a competitive landscape where the company must continually refine its strategies.
Ultragenyx Pharmaceutical s Groundbreaking Development in Pediatric HoFH Treatment Amidst Operational Challenges IntroductionIn a significant advancement for pediatric healthcare, the European Commission (EC) has extended the approval of Evkeeza (evinacumab) to children as young as six months diagnosed with Homozygous Familial Hypercholesterolemia (HoFH). This ultrarare genetic disorder is characterized by extremely high cholesterol levels, leading to severe cardiovascular complications. The approval positions Evkeeza as the first and only medication authorized in the European Union for this age group, marking a crucial milestone in the treatment of HoFH. Key Developments- Approval of Evkeeza: The EC s approval allows for the administration of Evkeeza to pediatric patients aged between six months to five years, addressing an urgent medical need among children suffering from HoFH. This decision is particularly notable given the rarity of the condition, which presents a unique challenge to both patients and healthcare providers.
Ultragenyx Pharmaceutical Inc. a leader in the development of innovative gene therapies for rare genetic diseases, has made a significant move in the field of genetic therapeutics with the submission of a Biologics License Application to the U.S. FDA for its investigational gene therapy, UX111. This application is aimed at treating Sanfilippo Syndrome Type A (MPS IIIA), a rare and progressive neurodegenerative disorder that severely affects children s cognitive and physical development. If approved, UX111 would mark a milestone as the first approved therapy specifically for Sanfilippo Syndrome Type A in the U.S. marketplace—a critical development for patients and families affected by this debilitating condition.Despite this promising progress, Ultragenyx faced a challenging financial landscape, with its share price reported to have declined by -13.94% during the fourth quarter of 2024. The company’s business performance was highlighted by a significant increase in revenue per employee, now estimated at $409,675, which marks a 42.27% increase in revenue in the third quarter of 2024, compared to the same period the previous year. This translates to a cumulative revenue high of $523 million, reflecting the company’s ongoing commitment to innovation and growth within the rare disease treatment sector. Currently, Ultragenyx employs 1,276 individuals, and while its revenue per employee demonstrates commendable productivity, the company s overall ranking in comparison to its peers in the healthcare sector has worsened, dropping to 143 from its previous standing in the second quarter of 2024. Among 143 other companies examined within the same industry, Ultragenyx s revenue generation per employee still ranks lower, underscoring the competitive challenges it faces as it continues to bring breakthrough therapies to market.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
